Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90

Cell Stress and Chaperones

Volumn 22, Issue 1, 2017, Pages 113-122

  Braga, Ana Claudia Silva ^a   Carneiro, Bruno Moreira ^a,b   Batista, Mariana Nogueira ^a   Akinaga, Mônica Mayumi ^a   Rahal, Paula ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Mato Grosso Federal University   (Brazil)

Author keywords

HCV; Heat shock protein; Hepatitis C; Hsp90; RNA interference; siRNA

Indexed keywords

HEAT SHOCK PROTEIN 90; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; SMALL INTERFERING RNA; VIRAL PROTEIN; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS;

5' UNTRANSLATED REGION; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; GENE EXPRESSION; GENE SILENCING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MTT ASSAY; PRIORITY JOURNAL; RNA INTERFERENCE; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; GENETICS; HEPACIVIRUS; METABOLISM; TUMOR CELL LINE;

5' UNTRANSLATED REGIONS; CELL LINE, TUMOR; CELL SURVIVAL; HEPACIVIRUS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84995784281     PISSN: 13558145     EISSN: 14661268     Source Type: Journal    
DOI: 10.1007/s12192-016-0747-8     Document Type: Article

References (51)

1. Ansar M et al (2011) Inhibition of full length hepatitis C virus particles of 1a genotype through small interference RNA. Virol J 8:203. doi:10.1186/1743-422X-8-203
2. Araujo FM, Sonoda IV, Rodrigues NB, Teixeira R, Redondo RA, Oliveira GC (2008) Genetic variability in the 5′ UTR and NS5A regions of hepatitis C virus RNA isolated from non-responding and responding patients with chronic HCV genotype 1 infection. Memorias do Instituto Oswaldo Cruz 103:611–614
3. Bartenschlager R, Frese M, Pietschmann T (2004) Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 63:71–180. doi:10.1016/S0065-3527(04)63002-8
4. Beck J, Nassal M (2003) Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein. J Biol Chem 278:36128–36138. doi:10.1074/jbc.M301069200
5. Bian Z et al (2012) Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70. Virol J 9:275. doi:10.1186/1743-422X-9-275
6. Brown KM, Chu CY, Rana TM (2005) Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol 12:469–470. doi:10.1038/nsmb931
7. Bukowska-Osko I et al (2015) Genetic variability of hepatitis C virus (HCV) 5′ untranslated region in HIV/HCV Coinfected patients treated with Pegylated interferon and ribavirin. PLoS One 10:e0125604. doi:10.1371/journal.pone.0125604
8. Caffrey DR et al (2011) siRNA off-target effects can be reduced at concentrations that match their individual potency. PLoS One 6:e21503. doi:10.1371/journal.pone.0021503
9. Carneiro B, Braga AC, Batista MN, Harris M, Rahal P (2015) Evaluation of canonical siRNA and dicer substrate RNA for inhibition of hepatitis C virus genome replication--a comparative study. PLoS One 10:e0117742. doi:10.1371/journal.pone.0117742
10. Chandra PK, Kundu AK, Hazari S, Chandra S, Bao L, Ooms T, Morris GF, Wu T, Mandal TK, Dash S (2012) Inhibition of hepatitis c virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther 20(9):1724–1736
11. Chen B, Piel WH, Gui L, Bruford E, Monteiro A (2005) The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 86:627–637. doi:10.1016/j.ygeno.2005.08.012
12. Chen ZW, Li H, Ren H, Hu P (2016) Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Scientific reports 6:20310. doi:10.1038/srep20310
13. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R (2013) Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 158:114–123
14. Duan L, Yan Y, Liu J, Wang B, Li P, Hu Q, Chen W (2016) Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C. Scientific reports 6:24867. doi:10.1038/srep24867
15. Giannini C, Brechot C (2003) Hepatitis C virus biology. Cell Death Differ 10(Suppl 1):S27–S38. doi:10.1038/sj.cdd.4401121
16. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57. doi:10.1016/j.jhep.2014.07.027
17. Gredell JA, Berger AK, Walton SP (2008) Impact of target mRNA structure on siRNA silencing efficiency: a large-scale study. Biotechnol Bioeng 100:744–755. doi:10.1002/bit.21798
18. Haupt A et al (2012) Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer 12:38. doi:10.1186/1471-2407-12-38
19. Imran M et al (2014) Current and future therapies for hepatitis C virus infection: from viral proteins to host targets. Arch Virol 159:831–846. doi:10.1007/s00705-013-1803-7
20. Kampinga HH et al (2009) Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 14:105–111. doi:10.1007/s12192-008-0068-7
21. Khaliq S et al (2010) RNAi as a new therapeutic strategy against HCV. Biotechnol Adv 28:27–34. doi:10.1016/j.biotechadv.2009.08.004
22. Konishi M, Wu CH, Kaito M, Hayashi K, Watanabe S, Adachi Y, Wu GY (2006) siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations. J Viral Hepat 13:756–761. doi:10.1111/j.1365-2893.2006.00752.x
23. Li Z et al (2014) Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors. Eur J Med Chem 85:359–370. doi:10.1016/j.ejmech.2014.07.101
24. Li Y, Yamane D, Masaki T, Lemon SM (2015) The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA nature reviews. Microbiology 13:544–558. doi:10.1038/nrmicro3506
25. Lozano R et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:2095–2128. doi:10.1016/S0140-6736(12)61728-0
26. Moriishi K, Matsuura Y (2007) Host factors involved in the replication of hepatitis C virus. Rev Med Virol 17:343–354. doi:10.1002/rmv.542
27. Motavaf M, Safari S, Alavian SM (2012) Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C. J Viral Hepat 19:757–765. doi:10.1111/jvh.12006
28. Naito Y, Yoshimura J, Morishita S, Ui-Tei K (2009) siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC bioinformatics 10:392. doi:10.1186/1471-2105-10-392
29. Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M (2007) Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 353:882–888. doi:10.1016/j.bbrc.2006.12.117
30. Okamoto T et al (2006) Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 25:5015–5025. doi:10.1038/sj.emboj.7601367
31. Overhoff M, Alken M, Far RK, Lemaitre M, Lebleu B, Sczakiel G, Robbins I (2005) Local RNA target structure influences siRNA efficacy: a systematic global analysis. J Mol Biol 348:871–881. doi:10.1016/j.jmb.2005.03.012
32. Prabhu R, Vittal P, Yin Q, Flemington E, Garry R, Robichaux WH, Dash S (2005) Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full-length hepatitis C virus clone. J Med Virol 76:511–519. doi:10.1002/jmv.20391
33. Prodromou C (2016) Mechanisms of Hsp90 regulation. The Biochemical journal 473:2439–2452. doi:10.1042/BCJ20160005
34. Radhakrishnan SK, Layden TJ, Gartel AL (2004) RNA interference as a new strategy against viral hepatitis. Virology 323:173–181. doi:10.1016/j.virol.2004.02.021
35. Samreen B et al (2012) Hepatitis C virus entry: role of host and viral factors. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases 12:1699–1709. doi:10.1016/j.meegid.2012.07.010
36. Simmonds P (2013) The origin of hepatitis C virus. Curr Top Microbiol Immunol 369:1–15. doi:10.1007/978-3-642-27340-7_1
37. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239–250
38. Sulkowski MS, Jacobson IM, Nelson DR (2014) Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 370:1560–1561. doi:10.1056/NEJMc1401726
39. Sun X et al (2010) Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc Natl Acad Sci U S A 107:3146–3151. doi:10.1073/pnas.0910717107
40. Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT (2009) A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5:298–307. doi:10.1016/j.chom.2009.02.001
41. Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11:515–528. doi:10.1038/nrm2918
42. Torrecilla J et al (2016) Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES) colloids and surfaces B. Biointerfaces 146:808–817. doi:10.1016/j.colsurfb.2016.07.026
43. Ujino S, Yamaguchi S, Shimotohno K, Takaku H (2009) Heat-shock protein 90 is essential for stabilization of the hepatitis C virus nonstructural protein NS3. J Biol Chem 284:6841–6846. doi:10.1074/jbc.M806452200
44. Wakita T et al (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796. doi:10.1038/nm1268
45. Waxman L, Whitney M, Pollok BA, Kuo LC, Darke PL (2001) Host cell factor requirement for hepatitis C virus enzyme maturation. Proc Natl Acad Sci U S A 98:13931–13935. doi:10.1073/pnas.241510898
46. Wen KW, Damania B (2010) Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1. Oncogene 29:3532–3544. doi:10.1038/onc.2010.124
47. Workman P, Burrows F, Neckers L, Rosen N (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113:202–216. doi:10.1196/annals.1391.012
48. Wyles DL, Kaihara KA, Korba BE, Schooley RT, Beadle JR, Hostetler KY (2009) The octadecyloxyethyl Ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons. Antimicrob Agents Chemother 53:2660–2662. doi:10.1128/AAC.01546-08
49. Xing XK, Li SJ, He JL, Chen Z (2012) Inhibition of hepatitis C virus replication by single and dual small interfering RNA using an HCV-infected cell model. Biotechnol Lett 34:295–301. doi:10.1007/s10529-011-0761-y
50. Yao JQ et al (2010) Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells. J Biomed Sci 17:30. doi:10.1186/1423-0127-17-30
51. Yokota T et al (2003) Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 4:602–608. doi:10.1038/sj.embor.embor840